Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclobenzaprine
Drug ID BADD_D00545
Description Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977.[A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Indications and Usage For use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Marketing Status Prescription; Discontinued
ATC Code M03BX08
DrugBank ID DB00924
KEGG ID D07758
MeSH ID C004704
PubChem ID 2895
TTD Drug ID D01KHH
NDC Product Code 68071-3150; 63187-812; 0615-8084; 61919-305; 69097-845; 69097-846; 51927-0118; 70518-0635; 58118-0846; 53002-3080; 53002-0521; 67296-1728; 70518-3159; 68071-3154; 60687-558; 50090-3253; 70934-005; 70518-0082
Synonyms cyclobenzaprine | Flexeril | Lisseril | cyclobenzaprine hydrochloride
Chemical Information
Molecular Formula C20H21N
CAS Registry Number 303-53-7
SMILES CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.0030.000295%
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Libido increased21.03.02.007; 19.08.03.002--
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Muscle spasms15.05.03.0040.000098%
Muscle twitching15.05.03.005--Not Available
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.0050.000066%Not Available
Neuropathy peripheral17.09.03.003--Not Available
Nightmare19.02.03.0030.000066%Not Available
Oedema08.01.07.006; 14.05.06.0100.000066%Not Available
Osteoarthritis15.01.04.001--Not Available
Pain08.01.08.004--
Palpitations02.01.02.0030.000164%
Pancytopenia01.03.03.003--Not Available
Paraesthesia17.02.06.005--
Paranoia19.05.01.005--Not Available
Parotid gland enlargement07.06.03.001--Not Available
Pharyngeal oedema22.04.05.003; 10.01.05.016; 23.04.01.0160.000066%Not Available
Pharyngitis07.05.07.004; 22.07.03.004; 11.01.13.003--
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages